|
|
15405 SE 37th Street, Suite 100
Bellevue, Washington 98006 USA
phone:425-957-8900
fax:425-957-8999
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.lsoncology.com/
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Light Sciences Oncology is developing Light Infusion Therapy (Litx), an innovative light-activated drug treatment for solid tumors, designed to provide safer and more effective treatment to cancer patients. |
|
| Management |
| Llew Keltner, President, CEO and Director; Jay Winship, Chief Medical Officer; James Chen, Chief Scientific Officer; Robert Littauer, VP Chief Financial Officer; Sy-Shi Wang, VP Clinical Development; Erik Hagstrom, VP Operations |
| |
|
|
| |
|
| Keywords |
| Solid tumors, Cancer, Hepatocellular carcinoma, Hyperplasia, Uterine fibroids, Vascular disease |
|
|
|
| Description |
|
Light Sciences Oncology is developing Light Infusion Therapy (Litx), an innovative light-activated drug treatment for solid tumors, designed to provide safer and more effective treatment to cancer patients. In addition to Phase III trials underway in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the company has completed a Phase II clinical trial of Litx in glioma. LSO has expanded the scope of potential therapeutic applications of its versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia and uterine fibroids, as well as vascular disease and dermatology. The company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented tea |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members